Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The value of subcutaneous alnuctamab for the treatment of R/R multiple myeloma

Claudio Cerchione • 12 Dec 2022
ASH 2022
Multiple Myeloma Alnuctamab Antibodies

Claudio Cerchione MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses results from the first-in-human Phase I study of subcutaneously administered alnuctamab for the treatment of relapsed/refractory (R/R) multiple myeloma (NCT03486067), and further explains the value of this agent in the myeloma treatment armamentarium. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Claudio Cerchione

6:48
Key trials in multiple myeloma presented at ASH 2023: take home messages
Claudio Cerchione • 11 Dec 2023
4:58
Novel immunotherapies transforming R/R myeloma treatment: bispecifics, CAR-T cells & more
Claudio Cerchione • 28 Sep 2023
3:15
Promising triplets and agents in R/R myeloma: SVd, Isa-Kd and melflufen
Claudio Cerchione • 28 Sep 2023
2:34
The role of FDG-PET plus whole body MRI in staging patients with high-risk SMM & R/R myeloma
Claudio Cerchione • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals